"Revlimid is a more potent version of thalidomide, which is sold by Celgene and used mainly to treat the blood cancer multiple myeloma. For patients with myelodysplastic syndromes (MDS), another group of blood malignancies, the new pill means fewer transfusions. In patients with a particular genetic defect, called 5q- syndrome, the drug proved very effective in a mid-stage trial." [1] (http://www.forbes.com/sciencesandmedicine/2004/01/23/cx_mh_rl_cancertear_9.html)
"March 4th 2004. Celgene’s (NASDAQ: CELG) Revlimid (CC-5013, formerly Revimid) has been granted orphan drug designation for myelodysplastic syndromes (MDS) by the European Commission (EC). Last month, the EC granted Revlimid orphan drug designation for multiple myeloma. Revlimid has demonstrated initial utility for managing the refractory anemia component of MDS. Except for Millennium’s (NASDAQ: MLNM) Velcade, Revlimid is the most likely novel biological agent to significantly impact the future management of multiple myeloma." [2] (http://www.bioportfolio.com/news/biotracker_236.htm)
External links and references
IMiDs (http://www.multiplemyeloma.org/treatments/3.08.02.html) Immunomodulatory Drugs are a group of oral drugs that are chemically similar to thalidomide"
Medical News (http://www.news-medical.net/?id=6741)
In a recent trial of Revlimid in previously untreated patients with myeloma, aspirin appeared to be successful as prophylaxis, although further studies in larger numbers of patients are necessary for formal recommendations.
Revlimid® was awarded Fast Track designation for relapsed and refractory myeloma in February 2003, which means that the FDA will facilitate and expedite the development and review of the application.
Revlimid is being evaluated in combination with Doxil® (liposomal doxorubicin, Ortho-Biotech), vincristine, and reduced frequency dexamethasone (DVd) in relapsed and refractory myeloma in a Phase I/II study at the Cleveland Clinic.
Feeds |
Contact